ClinicalTrials.govrestricted
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
ClinicalTrials.gov study NCT05862194. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ShareScore
20/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4